Federated Hermes Inc. Has $43.28 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Federated Hermes Inc. lifted its stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 12.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,599,450 shares of the company’s stock after acquiring an additional 513,870 shares during the quarter. Federated Hermes Inc. owned approximately 6.67% of Eyepoint Pharmaceuticals worth $43,281,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. American Century Companies Inc. acquired a new position in Eyepoint Pharmaceuticals in the 1st quarter worth about $232,000. Invesco Ltd. grew its stake in shares of Eyepoint Pharmaceuticals by 174.3% in the 1st quarter. Invesco Ltd. now owns 42,948 shares of the company’s stock valued at $233,000 after buying an additional 27,291 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in Eyepoint Pharmaceuticals by 127.8% in the first quarter. Dynamic Technology Lab Private Ltd now owns 73,310 shares of the company’s stock worth $397,000 after buying an additional 41,132 shares during the last quarter. Vanguard Group Inc. raised its position in Eyepoint Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company’s stock valued at $20,782,000 after acquiring an additional 31,141 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Eyepoint Pharmaceuticals in the first quarter valued at approximately $180,000. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. Mizuho set a $28.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Monday, October 20th. Royal Bank Of Canada upped their price objective on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Eyepoint Pharmaceuticals Trading Up 0.5%

NASDAQ:EYPT opened at $17.82 on Tuesday. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $19.11. The firm’s fifty day simple moving average is $13.15 and its 200 day simple moving average is $11.46. The firm has a market capitalization of $1.48 billion, a PE ratio of -5.96 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, November 5th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 76.13% and a negative net margin of 485.95%.The firm had revenue of $0.97 million for the quarter, compared to analyst estimates of $3.33 million. As a group, analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.